TIDMEVG
RNS Number : 3416L
Evgen Pharma PLC
05 September 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group)
Directorate Changes: Retirement of Chair, Appointment of Interim
Chair and of Interim CFO
Alderley Park, UK - 5 September 2023: Evgen Pharma plc (AIM:
EVG), a clinical stage drug development company developing
sulforaphane-based medicines, announces that Non-Executive Chair,
Barry Clare, will be retiring as Chairman of the Board and a
director of the Company at the next board meeting on 21 September
2023. The role of Chair will be passed to Dr Susan Foden, currently
Senior Non-executive Director, on an interim basis.
The Company also announces the appointment of Toni Hänninen as
interim Chief Financial Officer.
Barry was appointed Non-Executive Chair at the foundation of
Evgen in 2007 and has overseen the evolution of the Company and
board, including the IPO on AIM in October 2015 and more recently
the partnership with Stalicla SA exploring the potential
therapeutic benefit of sulforaphane in autism.
Susan Foden, the incoming interim Chair, has considerable
experience as a non-executive director working with public and
private companies. Susan has held NED roles at Vectura plc,
BerGenBio AS, BTG plc and, recently served as Chair of Neurocentrx
Ltd. She is currently Non-executive Deputy Chair of Australian
biotech QBiotics, an Investment Committee member of CD3, the drug
discovery initiative between the European Investment Fund and the
University of Leuven in Belgium and a Trustee of the Roslin
Foundation in Edinburgh, UK.
New CFO
Evgen Pharma also confirms that Toni Hänninen will take over as
interim CFO following Richard Moulson's retirement in July. Toni
was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq
First North listed clinical stage biopharmaceutical company based
in the Finland and the US developing novel treatments for medical
conditions with significant unmet needs. He holds over 20 years of
experience in business development and senior finance roles in both
public and private companies, working in mature and emerging
markets particularly in Europe and the USA where he has
accomplished successful fundraises, transactions and fiscal
management in the sector. Toni has an MBA from the Helsinki School
of Economics (currently Aalto University).
Dr Huw Jones, CEO of Evgen Pharma said:
"On behalf of the Board, I would like to thank Barry for his
considerable work with Evgen since inception. His support and
guidance have been invaluable to the Board, and we wish him well
for the future.
"Our Senior NED, Susan Foden has agreed to take over as Chair of
the Board whilst the search for a permanent successor is underway.
Sue is already an integral member of the Board sharing her broad
experience from across the biotech sector.
"I'm also pleased to welcome Toni Hänninen to the Company as
interim CFO. His proven experience in the AIM market and beyond
will be invaluable to us as we enter the next phase of our
development."
Toni Hänninen commented: "I am very excited to join the Evgen
team and to support the Company development going forward. I am
impressed by the highly experienced team and the board of
directors, and the Company strategy of demonstrating proof of
concept and concluding partnerships with larger organisations to
accelerate the development of SFX-01 to the market."
Barry Clare, retiring Chairman of Evgen said: "It has been a
privilege to serve as Chair of Evgen and see some great
achievements made by the Company. I remain confident that Evgen
will soon be able to demonstrate the anti-cancer benefits of
sulforaphane with its unique pharmaceutical formulations, and I am
encouraged by the recent results in glioblastoma and the
collaboration with Erasmus in Rotterdam. I want to thank the team
for their hard work and commitment and add my thanks to our many
external academic partners, especially the Christie Hospital in
Manchester. I look forward to watching Evgen's development in the
future."
Susan Foden added: "I have very much enjoyed working alongside
Barry on the board of Evgen and his leadership has been much
valued. I am looking forward to the challenges of this new role as
the Company continues along its development pathway."
-ENDS-
Enquiries:
Evgen Pharma PLC
Dr Huw Jones, CEO
Dr Helen Kuhlman CBO +44 1625 466591
FinnCap (Nominated Advisor and Broker)
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris/ Adam Loudon Evgen@Instinctif.com
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZLFBXKLZBBD
(END) Dow Jones Newswires
September 05, 2023 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Evgen Pharma (LSE:EVG)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
